Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3%) patient with a germline RET variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32–NR (not reached); n = 36), and the median PFS was 21 months (12–39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13–79; n = 22), and the median PFS was 3.5 months (2–14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.
21 April 2026 in The Journal of Clinical Endocrinology & Metabolism
Context: Prognosis of anaplastic thyroid cancer (ATC) remains poor. In the absence of immediately actionable molecular alterations, guidelines recommend multimodal therapy including radiotherapy and cytotoxic chemotherapy, but optimal regimens are not established. Many centers in Germany have adopted carboplatin/paclitaxel (CP), with or without radiotherapy, as a preferred first-line approach. Objective: This study aims to compare the outcome of patients treated first-line with CP ± radiotherapy vs other cytotoxic chemotherapy regimens in ATC. Design: Retrospective multicenter registry study in Germany. Setting and patients: 158 adults with histologically confirmed ATC treated with first-line cytotoxic chemotherapy at 7 German tertiary centers (2000-2024). Main Outcome Measures: Progression-free survival (PFS) and overall survival (OS) were compared with Kaplan–Meier and log-rank tests; a Cox proportional hazard model was used to identify risk factors. Results: 97 patients received first-line CP, and 61 received other chemotherapy. PFS (102 vs 89 days; log-rank P = .23) and OS (278 vs 295 days; P = .50) did not differ between CP and other regimens. Complete response occurred in 13% with CP and 8% with other chemotherapy (P = .46). In multivariable analyses, age ≥65 years, lymph node metastasis, and distant metastasis were associated with higher mortality risk. Surgery was associated with a lower mortality risk. CP was not associated with improved OS. The outcome of second-line treatment was not different for chemotherapy vs kinase inhibition ± immunotherapy. Conclusion: In this registry study, CP showed no survival benefit in ATC; outcomes depended on disease burden and resectability, underscoring the need for rapid molecular diagnostics. Chemotherapy may serve as a bridging strategy.